^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    1d
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    1d
    Protective effect of obeticholic acid on cyclophosphamide-induced thyroid toxicity in rats by inhibiting TXNIP/NLRP3/ASC/caspase-1-dependent pyroptosis and p53/BAX/caspase-3-dependent apoptosis. (PubMed, Biomed Pharmacother)
    Mechanistically, OCA suppressed inflammation via downregulation of TLR4/MYD88/NF-κB signalling, inhibited pyroptosis through TXNIP/NLRP3/ASC/caspase-1 pathway blockade and reduced p53-mediated apoptosis by modulating BAX, BCL-2 and cleaved caspase-3 expression. This study provides the first evidence that OCA confers protection against CYC-induced thyroid injury by reducing oxidative stress, inflammation, pyroptosis and apoptosis.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IL18 (Interleukin 18) • TLR4 (Toll Like Receptor 4) • NLRP3 (NLR Family Pyrin Domain Containing 3) • TXNIP (Thioredoxin Interacting Protein) • CASP1 (Caspase 1)
    |
    cyclophosphamide
    1d
    Uro-Protective Role of Lacosamide Against Cyclophosphamide-Induced Cystitis via Notch1/NICD/NF-κB Pathway: Network Pharmacology, Molecular Docking, and Rat Model Validation. (PubMed, Arch Pharm (Weinheim))
    Histopathological examination corroborated biochemical findings. Lacosamide demonstrates significant uro-protective efficacy through coordinated anti-inflammatory, antioxidant, and anti-apoptotic mechanisms through modulation of Notch-1/NICD/NF-κB pathway.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • NOTCH1 (Notch 1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • NICD (NOTCH1 intracellular domain)
    |
    cyclophosphamide
    2d
    ETNA: Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer (ACTRN12613000119796)
    P3, N=632, Completed, Fondazione Michelangelo | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    |
    doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    2d
    FT576 in Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1, N=31, Completed, Fate Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT576
    2d
    Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery (clinicaltrials.gov)
    P2, N=20, Completed, University of Nebraska | Active, not recruiting --> Completed | Trial completion date: Nov 2026 --> Dec 2025
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel • cyclophosphamide • Trazimera (trastuzumab-qyyp)
    3d
    Unicentric Castleman disease with paraneoplastic pemphigus and follicular dendritic cell sarcoma: A case report. (PubMed, Oncol Lett)
    Initial therapy comprised high-dose methylprednisolone, intravenous immunoglobulin and thalidomide, followed by surgical resection and adjuvant thalidomide-cyclophosphamide-prednisone. Postoperatively, inflammatory indices normalized and mucocutaneous lesions partially improved; nevertheless, the patient died of respiratory failure 6 months after surgery. In summary, the present case report aimed to provide valuable references and experiences for clinicians in the diagnosis and treatment of CD featuring PNP and FDCS.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CD68 (CD68 Molecule) • CR1 (Complement C3b/C4b Receptor 1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    cyclophosphamide • thalidomide • methylprednisolone sodium succinate
    3d
    DP13 Keep calm and shoulder on: a lesion that can't be shrugged off. (PubMed, Br J Dermatol)
    The second cycle of adjuvant chemotherapy (5-fluorouracil, epirubicin, cyclophosphamide) caused right-upper-limb phlebitis and lymphangitis with permanent damage to local vasculature...She was on hydroxychloroquine for long-standing rheumatoid arthritis, having previously received methotrexate and sulfasalazine...Some cases described in the literature as APL in irradiated areas are possibly the lymphatic subtype of an AVL. As there was no latency between irradiation and onset, our case is more likely APL, rather than AVL outside the field of irradiation.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    5-fluorouracil • cyclophosphamide • methotrexate • epirubicin • hydroxychloroquine
    3d
    DARLING-02: Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） (clinicaltrials.gov)
    P2, N=144, Recruiting, Hebei Medical University Fourth Hospital | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Head-to-Head
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cyclophosphamide • epirubicin • AiRuiKang (dalpiciclib)
    3d
    FT819 in Subjects With B-cell Malignancies (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Fate Therapeutics | Trial primary completion date: Sep 2024 --> Jun 2025
    Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • FT819
    3d
    A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital) (clinicaltrials.gov)
    P1, N=50, Recruiting, Shanghai Juncell Therapeutics | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide
    3d
    Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    cyclophosphamide • thiotepa • busulfan